W. Va. Code R. § 64-110-11 - Limit on medical cannabis processing
11.1. In the form intended to be sold to
another medical cannabis organization, medical cannabis must have a specific
concentration of total THC and total CBD and must have a consistent cannabinoid
profile. The concentration of the following cannabinoids, at a minimum, must be
reported to the Bureau by an approved laboratory and include the following on
the label:
11.1.1. Tetrahydrocannabinol
(THC);
11.1.2. Tetrahydrocannabinol
acid (THCA);
11.1.3.
Tetrahydrocannabivarin (THCV);
11.1.4. Cannabidiol (CBD);
11.1.5. Cannabinadiolic acid
(CBDA);
11.1.6. Cannabidivarine
(CBDV);
11.1.7. Cannabinol
(CBN);
11.1.8. Cannabigerol (CBG);
11.1.9. Cannabichromene (CBC);
and
11.1.10. Any other cannabinoid
component at 0.1 percent.
11.2. Within the first six months after the
Bureau determines the grower/processor to be operational, the grower/processor
must provide the Bureau with a forecast of the amount of medical cannabis it
projects it will produce and in what form. The grower/processor must notify the
Bureau in writing immediately upon becoming aware of a potential increase or
decrease in the forecasted amount occurring within any subsequent six-month
period.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
11.1. In the form intended to be sold to another medical cannabis organization , medical cannabis must have a specific concentration of total THC and total CBD and must have a consistent cannabinoid profile. The concentration of the following cannabinoids, at a minimum, must be reported to the bureau by an approved laboratory and include the following on the label:
11.1.a. Tetrahydrocannabinol (THC);
11.1.b. Tetrahydrocannabinol acid (THCA);
11.1.c. Tetrahydrocannabivarin (THCV);
11.1.d. Cannabidiol (CBD);
11.1.e. Cannabinadiolic acid (CBDA);
11.1.f. Cannabidivarine (CBDV);
11.1.g. Cannabinol (CBN);
11.1.h. Cannabigerol (CBG);
11.1.i. Cannabichromene (CBC); and
11.1.j. Any other cannabinoid component at 0.1 percent.
11.2. Within the first six months after the bureau determines the grower/processor to be operational, the grower/processor must provide the bureau with a forecast of the amount of medical cannabis it projects it will produce and in what form. The grower/processor must notify the bureau in writing immediately upon becoming aware of a potential increase or decrease in the forecasted amount occurring within any subsequent six-month period.